Cargando…

Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients

PURPOSE: To ensure target coverage in the treatment of esophageal cancer, a density override to the region of diaphragm motion can be applied in the optimization process. Here, we evaluate the benefit of this approach during robust optimization for intensity modulated proton therapy (IMPT) planning....

Descripción completa

Detalles Bibliográficos
Autores principales: Visser, Sabine, Neh, Hendrike, Oraboni Ribeiro, Cássia, Korevaar, Erik W., Meijers, Arturs, Poppe, Björn, Sijtsema, Nanna M., Both, Stefan, Langendijk, Johannes A., Muijs, Christina T., Knopf, Antje C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291176/
https://www.ncbi.nlm.nih.gov/pubmed/34289123
http://dx.doi.org/10.1002/mp.15114
_version_ 1784749083584364544
author Visser, Sabine
Neh, Hendrike
Oraboni Ribeiro, Cássia
Korevaar, Erik W.
Meijers, Arturs
Poppe, Björn
Sijtsema, Nanna M.
Both, Stefan
Langendijk, Johannes A.
Muijs, Christina T.
Knopf, Antje C.
author_facet Visser, Sabine
Neh, Hendrike
Oraboni Ribeiro, Cássia
Korevaar, Erik W.
Meijers, Arturs
Poppe, Björn
Sijtsema, Nanna M.
Both, Stefan
Langendijk, Johannes A.
Muijs, Christina T.
Knopf, Antje C.
author_sort Visser, Sabine
collection PubMed
description PURPOSE: To ensure target coverage in the treatment of esophageal cancer, a density override to the region of diaphragm motion can be applied in the optimization process. Here, we evaluate the benefit of this approach during robust optimization for intensity modulated proton therapy (IMPT) planning. MATERIALS AND METHODS: For 10 esophageal cancer patients, two robustly optimized IMPT plans were created either using (WDO) or not using (NDO) a diaphragm density override of 1.05 g/cm(3) during plan optimization. The override was applied to the excursion of the diaphragm between exhale and inhale. Initial robustness evaluation was performed for plan acceptance (setup errors of 8 mm, range errors of ±3%), and subsequently, on all weekly repeated 4DCTs (setup errors of 2 mm, range errors of ±3%). Target coverage and hotspots were analyzed on the resulting voxel‐wise minimum (Vw(min)) and voxel‐wise maximum (Vw(max)) dose distributions. RESULTS: The nominal dose distributions were similar for both WDO and NDO plans. However, visual inspection of the Vw(max) of the WDO plans showed hotspots behind the right diaphragm override region. For one patient, target coverage and hotspots improved by applying the diaphragm override. We found no differences in target coverage in the weekly evaluations between the two approaches. CONCLUSION: The diaphragm override approach did not result in a clinical benefit in terms of planning and interfractional robustness. Therefore, we do not see added value in employing this approach as a default option during robust optimization for IMPT planning in esophageal cancer.
format Online
Article
Text
id pubmed-9291176
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92911762022-07-20 Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients Visser, Sabine Neh, Hendrike Oraboni Ribeiro, Cássia Korevaar, Erik W. Meijers, Arturs Poppe, Björn Sijtsema, Nanna M. Both, Stefan Langendijk, Johannes A. Muijs, Christina T. Knopf, Antje C. Med Phys THERAPEUTIC INTERVENTIONS PURPOSE: To ensure target coverage in the treatment of esophageal cancer, a density override to the region of diaphragm motion can be applied in the optimization process. Here, we evaluate the benefit of this approach during robust optimization for intensity modulated proton therapy (IMPT) planning. MATERIALS AND METHODS: For 10 esophageal cancer patients, two robustly optimized IMPT plans were created either using (WDO) or not using (NDO) a diaphragm density override of 1.05 g/cm(3) during plan optimization. The override was applied to the excursion of the diaphragm between exhale and inhale. Initial robustness evaluation was performed for plan acceptance (setup errors of 8 mm, range errors of ±3%), and subsequently, on all weekly repeated 4DCTs (setup errors of 2 mm, range errors of ±3%). Target coverage and hotspots were analyzed on the resulting voxel‐wise minimum (Vw(min)) and voxel‐wise maximum (Vw(max)) dose distributions. RESULTS: The nominal dose distributions were similar for both WDO and NDO plans. However, visual inspection of the Vw(max) of the WDO plans showed hotspots behind the right diaphragm override region. For one patient, target coverage and hotspots improved by applying the diaphragm override. We found no differences in target coverage in the weekly evaluations between the two approaches. CONCLUSION: The diaphragm override approach did not result in a clinical benefit in terms of planning and interfractional robustness. Therefore, we do not see added value in employing this approach as a default option during robust optimization for IMPT planning in esophageal cancer. John Wiley and Sons Inc. 2021-08-05 2021-10 /pmc/articles/PMC9291176/ /pubmed/34289123 http://dx.doi.org/10.1002/mp.15114 Text en © 2021 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle THERAPEUTIC INTERVENTIONS
Visser, Sabine
Neh, Hendrike
Oraboni Ribeiro, Cássia
Korevaar, Erik W.
Meijers, Arturs
Poppe, Björn
Sijtsema, Nanna M.
Both, Stefan
Langendijk, Johannes A.
Muijs, Christina T.
Knopf, Antje C.
Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients
title Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients
title_full Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients
title_fullStr Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients
title_full_unstemmed Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients
title_short Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients
title_sort assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients
topic THERAPEUTIC INTERVENTIONS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291176/
https://www.ncbi.nlm.nih.gov/pubmed/34289123
http://dx.doi.org/10.1002/mp.15114
work_keys_str_mv AT vissersabine assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients
AT nehhendrike assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients
AT oraboniribeirocassia assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients
AT korevaarerikw assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients
AT meijersarturs assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients
AT poppebjorn assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients
AT sijtsemanannam assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients
AT bothstefan assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients
AT langendijkjohannesa assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients
AT muijschristinat assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients
AT knopfantjec assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients